Act4Biosimilars
We need to act together
Act4Biosimilars aims to close the gap and support making biologic medicines more available to all. We need you to join us to help drive this change and make a difference.
Since the introduction of biosimilars, they have transformed the lives of many patients by enabling affordable access to life-changing, advanced medicines. However, with increasing pressures on healthcare systems and the inequities and inequalities of access to biologic medicines that exist across the globe, not everyone is able to access the biologic treatments they need.
Act4Biosimilars Vision
A world in which patients have increased access to biologics by helping to accelerate biosimilar Approvability, Accessibility, Acceptability and Affordability.
Act4Biosimilars Mission
To increase the global adoption of biosimilars by at least 30 percentage points in 30+ countries by 2030.
The Roadmap to 2030
12 specific goals have been identified to improve the Approvability, Accessibility, Acceptability and Affordability of biosimilar medicines – the 4 As. By using the Act4Biosimilars Impact Index, you will be able to assess the favorability of each ‘A’ and understand the key actions that can be taken to drive biosimilar adoption at a country level.
Act4Biosimilars Impact Index
The Act4Biosimilars Impact Index monitors the progress made in 30 countries to increase biosimilar adoption by at least 30 percentage points by 2030. The Impact Index tracks the adoption of biosimilars in 30 target countries using metrics based on the 4As. Explore the Impact Index below to see the progress being made.
The Action Plan
Act4Biosimilars focuses on four key drivers of biosimilar adoption: Approvability, Accessibility, Acceptability and Affordability (the 4As). These represent the greatest opportunities to accelerate biosimilar adoption and form the foundation of the Action Plan.
The Action Plan is the global roadmap for Act4Biosimilars, and it gives you the strategies, tools, and activities to help achieve the Mission to increase global biosimilar adoption by at least 30 percentage points by 2030.
To see the current trends and opportunities across the 4As in the Americas region, explore the Act4Biosimilars Deep Dive Report.
Act4Biosimilars Steering Committee
Act4Biosimilars is led by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders representing views from around the world. It is supported by founding sponsor, Sandoz.
